Open Access Open Access  Restricted Access Subscription Access

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease


Affiliations
1 University of British Columbia, Vancouver, BC, Canada
2 Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada
3 Division of Nephrology, University of British Columbia, Vancouver, BC, Canada
4 Division of AIDS, University of British Columbia, Vancouver, BC, Canada
 

Although major advances have occurred in treating patients with hepatitis C virus (HCV) with the development of new directacting antivirals (DAAs), treatment of liver transplant recipients with HCV, human immunodeficiency virus (HIV) coinfection, and renal disease is challenging due to the lack of efficacy and safety data in this population. We report a case of successful HCV therapy in a postliver transplant HIV coinfected patient,with stage 4 chronic kidney disease, using an all-oral regimen of simeprevir, sofosbuvir, and ribavirin. The 51-year-old male achieved SVR24, and no specific HIV-related or transplant-related adverse events were documented during the treatment period. The new DAAs show promise for HIV coinfected patients and those with severe to end-stage renal disease (ESRD); however, robust clinical trials or large cohort studies will need to be conducted to confirm the efficacy and safety of these newer agents in this setting.
User
Notifications
Font Size

Abstract Views: 69

PDF Views: 0




  • Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease

Abstract Views: 69  |  PDF Views: 0

Authors

Anna Maruyama
University of British Columbia, Vancouver, BC, Canada
Trana Hussaini
University of British Columbia, Vancouver, BC, Canada
Nilufar Partovi
University of British Columbia, Vancouver, BC, Canada
Siegfried R. Erb
Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada
Vladimir Marquez Azalgara
Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada
Nadia Zalunardo
Division of Nephrology, University of British Columbia, Vancouver, BC, Canada
Neora Pick
Division of AIDS, University of British Columbia, Vancouver, BC, Canada
Mark Hull
Division of AIDS, University of British Columbia, Vancouver, BC, Canada
Eric M. Yoshida
Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada

Abstract


Although major advances have occurred in treating patients with hepatitis C virus (HCV) with the development of new directacting antivirals (DAAs), treatment of liver transplant recipients with HCV, human immunodeficiency virus (HIV) coinfection, and renal disease is challenging due to the lack of efficacy and safety data in this population. We report a case of successful HCV therapy in a postliver transplant HIV coinfected patient,with stage 4 chronic kidney disease, using an all-oral regimen of simeprevir, sofosbuvir, and ribavirin. The 51-year-old male achieved SVR24, and no specific HIV-related or transplant-related adverse events were documented during the treatment period. The new DAAs show promise for HIV coinfected patients and those with severe to end-stage renal disease (ESRD); however, robust clinical trials or large cohort studies will need to be conducted to confirm the efficacy and safety of these newer agents in this setting.